Advisory · Immunology
Anti-inflammatory franchise replacements are driving urgent buy-side activity.
Ambrosia provides senior-led advisory for immunology licensing, M&A, and strategic partnerships — backed by a proprietary database of 350 verified immunology transactions.
Deal Landscape
What immunology transactions actually look like.
Verified Transactions
350
Median Upfront
$82M
Key Structure Insight
Biosimilar cliff exposure is accelerating mid-pharma acquisition timelines
Selected Work
Immunology·Novel bispecific — global licensing with milestone structure optimization
Immunology·Autoimmune platform — buy-side target identification for mid-pharma
Related Insights
Research relevant to immunology.
Stay Informed
Get new deal intelligence and transaction insights as we publish them.
No spam. Unsubscribe anytime.
Discuss your immunology transaction.
We’ll meet you at peer level — anywhere in the world.